Previous 10 | Next 10 |
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: NeoGenomics, Inc. 2021 Q3 - Results - Earnings Call Presentation
NeoGenomics, Inc. (NEO) Q3 2021 Earnings Conference Call November 4, 2021, 8:30 AM ET Company Participants Mark Mallon - Chief Executive Officer George Cardoza - President, Lab Operations and COO Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Director, Investor...
NeoGenomics (NEO -15.6%) shares have reached a five-month low after the company’s Q3 2021 financials fell short of expectations for the first time in three quarters. The operator of cancer testing labs has revised the 2021 revenue guidance that has also failed to meet the analyst ...
NeoGenomics (NASDAQ:NEO): Q3 Non-GAAP EPS of -$0.08 beats by $0.01; GAAP EPS of -$0.17 misses by $0.01. Revenue of $121.34M (-3.3% Y/Y) misses by $3.75M. Press Release The Company revised its full-year 2021 guidance : Revenue form prior $490M- $510M to $482.5M -$487.5M vs consensus of $4...
Third-Quarter 2021 Results and Highlights: Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million Consolidated revenue decreased 3% due to the discontinuation of prior year COVID-19 revenue; consoli...
FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today an upcoming leadership team transition. William Bonello will be named Chief Financial...
NeoGenomics (NASDAQ:NEO) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.09 (compared to $0.06 in year ago quarter) and the consensus Revenue Estimate is $125.09M (-0.3% Y/Y). Over the last 2 years, NEO has beaten E...
ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...
Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid...
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2021, financial results on Thursday, November 4, 2021. The C...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...